CClinicalTrials.gg
Not yet recruitingNCT06042985CALCOR-RSOUpdated Sep 21, 2023

Comparison of the Absorption of Calcium Citrate and Calcium Carbonate in Patients With an RYGB, LSG, and OAGB

A Phase 4 interventional study of The absorption effect between calcium citrate and calcium carbonate in Calcium Citrate Absorption and Calcium Carbonate Absorption, sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by General Committee of Teaching Hospitals and Institutes, Egypt · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The precise impact of calcium absorption in relation to RYGB, SG, and OAGB remains under-researched in terms of statistical power and the diversity of BMS procedures considered. Therefore, this presents a critical area for future investigation to improve patient outcomes in BMS.

Read the detailed description

Calcium, predominantly absorbed in the duodenum and proximal jejunum, relies heavily on vitamin D and an acidic environment to facilitate absorption. With the increasing prevalence of bariatric metabolic surgery (BMS) procedures and their malabsorptive effects, the likelihood of fat-soluble vitamin malabsorption becomes heightened. This stems from bypassing the stomach, key absorption sites in the intestine, and the inefficient mixing of bile salts.

BMS is often associated with several bone metabolism disorders, including the acceleration of bone remodeling and turnover, bone loss, and decreased bone mineral density (BMD). Postoperative calcium supplementation can mitigate this bone loss over time. For instance, a study demonstrated the beneficial effect of calcium citrate following Roux-en-Y gastric bypass (RYGB). However, the study's statistical power was insufficient; thus, the BMS field still awaits further conclusive and robust research to establish definitive guidelines, which was highlighted in another study.

Moreover, substantial changes in gut hormones, such as peptide YY (PYY), glucagon-like peptide-1, and ghrelin, have been observed following RYGB, sleeve gastrectomy (SG), and One Anastomosis Gastric Bypass (OAGB). While these hormonal changes are typically associated with BMS's numerous positive metabolic benefits, they may also contribute to bone loss.

Consequently, the precise impact of calcium absorption in relation to RYGB, SG, and OAGB remains under-researched in terms of statistical power and the diversity of BMS procedures considered. Therefore, this presents a critical area for future investigation to improve patient outcomes in BMS.

02

Conditions studied

  • Calcium Citrate Absorption
  • Calcium Carbonate Absorption

Keywords

  • Calcium Citrate
  • bariatric surgery
  • Absorption
  • Calcium Carbonate
03

In context

Lead sponsor

General Committee of Teaching Hospitals and Institutes, Egypt is the lead sponsor of 31 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients aged 18-75 years old
  • After BMS surgery who had an RYGB, SG, or OAGB operation at least 12 months before the study.
  • Patients will be selected at random from the hospital's electronic patient system.

Exclusion criteria

Exclusion Criteria:

  • Patients on antacids during the study
  • Patients onH2 receptor antagonists during the study
  • Patients on proton pump inhibitors during the study
  • Patients with a previous oophorectomy,
  • Liver disease,
  • Renal disease,
  • Hypercalcemia,
  • Hyperthyroidism,
  • Hypothyroidism who require levothyroxine supplementation (Levothyroxine forms complexes with calcium)
  • Parathyroid disorders
  • Use of diuretics,
  • Use of calcitonin,
  • Use of corticosteroids,
  • Use of anabolic steroids,
  • Use of anticonvulsants within three months of the study
  • Heavy smokers (>10 cigarettes/day)
  • Abusing alcohol (>70 ml/day)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    RYGB arm: calcium citrate and calcium carbonate

    The absorption effect between calcium citrate and calcium carbonate in patients with a RYGB

    Drug: The absorption effect between calcium citrate and calcium carbonate

  • Active comparator
    LSG arm: calcium citrate and calcium carbonate

    The absorption effect between calcium citrate and calcium carbonate in patients with a LSG

    Drug: The absorption effect between calcium citrate and calcium carbonate

  • Active comparator
    OAGB arm: calcium citrate and calcium carbonate

    The absorption effect between calcium citrate and calcium carbonate in patients with a OAGB

    Drug: The absorption effect between calcium citrate and calcium carbonate

Interventions

  • DrugThe absorption effect between calcium citrate and calcium carbonate

    Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.

    Also known as: Elemental Calcium citrate, Elemental Calcium Carbonate, Chewable tablets

06

What researchers measure

Primary outcomes

  1. Elemental Calcium effects in blood serum (Peak Plasma Concentration (Cmax))

    In patients who have undergone bariatric surgery and are receiving elemental calcium supplementation in the form of citrate or carbonate, we observe variations in their blood serum with peak concentrations (Cmax) These changes provide insights into how effectively the body absorbs and utilizes calcium following supplementation.

    Time frame: 8 hours

  2. Elemental Calcium effects in Urine excretion (time curve (AUC))

    In patients who have undergone bariatric surgery and are receiving elemental calcium supplementation in the form of citrate or carbonate, we observe variations in their cumulative excretion of urinary calcium over time (AUC). These changes provide insights into how effectively the body absorbs and utilizes calcium following supplementation.

    Time frame: 8 hours

  3. Elemental Calcium effects in blood serum (Area under the plasma concentration)

    In patients who have undergone bariatric surgery and are receiving elemental calcium supplementation in the form of citrate or carbonate, we observe variations in their blood serum with Area under the plasma concentration (AUC) These changes provide insights into how effectively the body absorbs and utilizes calcium following supplementation.

    Time frame: 8 hours

07

Study locations

1 site
  • The surgical department of Medical Research Institute Hospital, Alexandria University
    Alexandria, Egypt
08

References and documents

Publications

  • Allied Health Sciences Section Ad Hoc Nutrition Committee; Aills L, Blankenship J, Buffington C, Furtado M, Parrott J. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis. 2008 Sep-Oct;4(5 Suppl):S73-108. doi: 10.1016/j.soard.2008.03.002. Epub 2008 May 19. No abstract available. PubMed 18490202 ↗
  • Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. Endocr Pract. 2019 Dec;25(12):1346-1359. doi: 10.4158/GL-2019-0406. Epub 2019 Nov 4. PubMed 31682518 ↗
  • Tondapu P, Provost D, Adams-Huet B, Sims T, Chang C, Sakhaee K. Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. Obes Surg. 2009 Sep;19(9):1256-61. doi: 10.1007/s11695-009-9850-6. Epub 2009 May 13. PubMed 19437082 ↗
  • Smelt HJ, Pouwels S, Smulders JF. The Clinical Dilemma of Calcium Supplementation After Bariatric Surgery: Calcium Citrate or Calcium Carbonate That Is the Question? Obes Surg. 2016 Nov;26(11):2781-2782. doi: 10.1007/s11695-016-2346-2. No abstract available. PubMed 27558620 ↗
  • Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, Stewart L, Rogers SJ, Carter JT, Posselt AM, Shoback DM, Sellmeyer DE. Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. J Bone Miner Res. 2015 Aug;30(8):1377-85. doi: 10.1002/jbmr.2467. Epub 2015 May 21. PubMed 25640580 ↗

Individual participant data

Plan to share: Yes — The analysis will be performed on a blinded dataset after completing the medical/scientific review. All protocol violations will be identified and resolved, and the dataset will be declared complete. All data will be collected in a data management system (Castor EDC, Amsterdam, The Netherlands; https://www.castoredc.com), handled according to Good Clinical Practice guidelines, Data Protection Directive certificate, and complied with Title 21 CFR Part 11. Furthermore, the data centers where all the research data will be stored are certified according to ISO27001, ISO9001, and Dutch NEN7510.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06042985
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Responsible party
Mohamed Hany Ashour (Principal Investigator, General Committee of Teaching Hospitals and Institutes, Egypt) — Principal investigator
First posted
Sep 21, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
Apr 1, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Sep 21, 2023

Study contacts

M Hany Ashour, MD
Contact
mohamed.ashour@alexu.edu.eg
+20 100 2600970
M Hany Ashour, MD
principal investigator · Alexandria University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion